Receptor Subtype for Vasopressin-Induced Release of Nitric Oxide From Rat Kidney
- 1 January 1997
- journal article
- research article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 29 (1) , 58-64
- https://doi.org/10.1161/01.hyp.29.1.58
Abstract
The vasopressin receptor subtype that causes nitric oxide (NO) release remains controversial. To elucidate this receptor-ligand interaction, we examined the effects of vasopressin receptor antagonists on vasopressin-induced release of NO from isolated perfused rat kidneys by using a sensitive chemiluminescence assay. Vasopressin increased renal perfusion pressure and NO signals in the perfusate in a dose-dependent manner. N G -Monomethyl- l -arginine abolished this increase in NO release; however, a similar increase in renal perfusion pressure induced by prostaglandin F 2α was not associated with the increase in NO release. OPC-21268, a V 1 receptor antagonist, significantly reduced the vasopressin-evoked renal vasoconstriction and NO release, whereas OPC-31260, a V 2 receptor antagonist, had no effects. Moreover, desmopressin, a selective V 2 receptor agonist, did not increase the NO signal. NO release by vasopressin was markedly attenuated in deoxycorticosterone acetate (DOCA)–salt hypertensive rat kidneys compared with control kidneys (10 −10 mol/L vasopressin: +0.8±0.3 versus +6.9±1.4 fmol/min per gram kidney, DOCA versus control; P <.001). Histochemical analysis for renal NO synthase revealed a substantial attenuation of the staining of endothelial NO synthase in DOCA-salt rats. These results directly demonstrate that vasopressin stimulates NO release via the endothelial V 1 receptor in the rat kidney.Keywords
This publication has 16 references indexed in Scilit:
- Long-term administration of L-arginine improves nitric oxide release from kidney in deoxycorticosterone acetate-salt hypertensive rats.Hypertension, 1994
- Induction of nitric oxide synthase by cyclic AMP in rat vascular smooth muscle cells.Journal of Clinical Investigation, 1994
- Vasodilatory effect of arginine vasopressin is mediated by nitric oxide in human forearm vessels.Journal of Clinical Investigation, 1993
- Molecular cloning and characterization of the constitutive bovine aortic endothelial cell nitric oxide synthase.Journal of Clinical Investigation, 1992
- Effects of OPC-21268, an orally effective vasopressin V1 receptor antagonist in humans.Hypertension, 1992
- Effects of a nonpeptide vasopressin antagonist (OPC-21268) on cytosolic Ca2+ concentration in vascular and cardiac myocytes.Hypertension, 1992
- Cellular mechanism of endothelin-1 release by angiotensin and vasopressin.Hypertension, 1991
- OPC-21268, an Orally Effective, Nonpeptide Vasopressin V1 Receptor AntagonistScience, 1991
- Vasopressin-mediated forearm vasodilation in normal humans. Evidence for a vascular vasopressin V2 receptor.Journal of Clinical Investigation, 1989
- Inhibition of muscle sympathetic nerve activity in humans by arginine vasopressin.Hypertension, 1987